Diagnostic and prognostic value of procalcitonin in community-acquired pneumonia

American Journal of the Medical Sciences

Volumn 343, Issue 1, 2012, Pages 30-35

  Horie, Masafumi ^a   Ugajin, Motoi ^b   Suzuki, Masaru ^a   Noguchi, Satoshi ^a   Tanaka, Wakae ^a   Yoshihara, Hisanao ^a   Kawakami, Masaki ^a   Kichikawa, Yoshiko ^a   Sakamoto, Yoshio ^a  

^a The Mutualaid Association of Public School Teachers)   (Japan)

^b Ichinomiya Nishi Hospital   (Japan)

Author keywords

A DROP; C reactive protein; Community acquired pneumonia; Etiology; Pneumococcus; Procalcitonin

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; PROCALCITONIN;

AGED; ARTICLE; BACTERIUM IDENTIFICATION; COMMUNITY ACQUIRED PNEUMONIA; DEMOGRAPHY; DIAGNOSTIC VALUE; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HORMONE BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PROGNOSIS; PROSPECTIVE STUDY; SCORING SYSTEM; STREPTOCOCCUS PNEUMONIA;

EID: 84855276071     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31821d33ef     Document Type: Article

References (25)

1. Becker K, Nylén E, White J, et al. Clinical review 167: procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 2004;89:1512-25. (Pubitemid 38507896)
2. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004;363:600-7. (Pubitemid 38264177)
3. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006;174:84-93. (Pubitemid 43955248)
4. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009;302:1059-66.
5. Moulin F, Raymond J, Lorrot M, et al. Procalcitonin in children admitted to hospital with community acquired pneumonia. Arch Dis Child 2001;84:332-6. (Pubitemid 32328629)
6. Hedlund J, Hansson L. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis. Infection 2000;28:68-73. (Pubitemid 30189610)
7. Masiá M, Gutiérrez F, Shum C, et al. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. Chest 2005;128:2223-9. (Pubitemid 41507563)
8. Krüger S, Ewig S, Papassotiriou J, et al. Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ. Respir Res 2009;10:65.
9. Boussekey N, Leroy O, Georges H, et al. Diagnostic and prognosticvalues of admission procalcitonin levels in community-acquired pneumonia in an intensive care unit. Infection 2005;33:257-63. (Pubitemid 41152186)
10. Huang DT, Weissfeld LA, Kellum JA, et al. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med 2008;52:48-58.e2.
11. Nylen E, Muller B, Becker K, Snider R. The future diagnostic role of procalcitonin levels: the need for improved sensitivity. Clin Infect Dis 2003;36:823-4, author reply 6-7.
12. Schuetz P, Widmer I, Chaudri A, et al. Prognostic value of procalcitonin in community-acquired pneumonia. Eur Respir J 2011;37:384-92.
13. [The JRS guidelines for the management of community acquired pneumonia in adults.] Nihon Kokyuki Gakkai Zasshi 2007;Suppl:2-85.
14. Usui K, Tanaka Y, Noda H, Ishihara T. [Comparison of three prediction rules for prognosis in community acquired pneumonia: Pneumonia Severity Index (PSI), CURB-65, and A-DROP.] Nihon Kokyuki Gakkai Zasshi 2009;47:781-5.
15. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-50. (Pubitemid 27044625)
16. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377-82. (Pubitemid 36560938)
17. Krüger S, Ewig S, Marre R, et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J 2008;31:349-55.
18. Müller F, Christ-Crain M, Bregenzer T, et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest 2010;138:121-9.
19. Lin SH, Lai CC, Tan CK, et al.Outcomes of hospitalized patients with bacteraemic and non-bacteraemic community-acquired pneumonia caused by Streptococcus pneumoniae. Epidemiol Infect 2010:1-10.
20. Tillett W, Francis T. Serological reactions in pneumonia with a nonprotein somatic fraction of pneumococcus. J Exp Med 1930;52:561-71.
21. García Vázquez E, Martínez J, Mensa J, et al. C-reactive protein levels in community-acquired pneumonia. Eur Respir J 2003;21:702-5. (Pubitemid 36432528)
22. Ortqvist A, Hedlund J, Wretlind B, et al. Diagnostic and prognostic value of interleukin-6 and C-reactive protein in community-acquired pneumonia. Scand J Infect Dis 1995;27:457-62.
23. Almirall J, Bolíbar I, Toran P, et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of communityacquired pneumonia. Chest 2004;125:1335-42. (Pubitemid 38501347)
24. Arnold F, Summersgill J, Lajoie A, et al. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med 2007;175:1086-93. (Pubitemid 46741761)
25. Ngeow Y, Suwanjutha S, Chantarojanasriri T, et al. An Asian study on the prevalence of atypical respiratory pathogens in community-acquired pneumonia. Int J Infect Dis 2005;9:144-53. (Pubitemid 40523759)